drugset / Trial / NCT04168944
Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to observe the efficacy and safety of lenvatinib in preventing high-risk recurrence of hepatocellular carcinoma patients after liver transplantation.The cases are from patients with hepatocellular carcinoma who underwent liver transplantation in the liver surgery department of Shanghai Renji Hospital. Patients enrolled in the study were randomly allocated in the lenvatinib group (54 patients) and the control group (54 patients) after stable condition.
Timeline
- Start
- 2019-11
- Primary completion
- 2022-09
- Completion
- 2022-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Background | Mycophenolate Mofetil | Small molecule | — | — |
| Background | Sirolimus | Small molecule | — | — |
| Background | ivermus | Unknown | — | — |